SCHEMBL3149165

SCHEMBL3149165

NC1=NC[C@@H](COc2ccc3c(c2)CC2CCCCC32)O1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HIF1A Q16665 1/20 0.33
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
NOS2 P35228 1/20 0.31
GPR84 Q9NQS5 1/20 0.31
TAAR1 Q96RJ0 1/20 0.30
MAOA P21397 1/20 0.30
MAOB P27338 1/20 0.30
PARP15 Q460N3 1/20 0.30
PARP10 Q53GL7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3149153 1.00 ALDH1A1 (0.33) ALDH1A1MAPTCYP2C9CYP2C19HSD17B10
SCHEMBL3138790 0.77 SMN1; SMN2 (0.41) ALDH1A1MAPTHSD17B10TP53TSHR
SCHEMBL3148352 0.77 ALOX15 (0.43) ALDH1A1MAPTHSD17B10TP53TSHR
SCHEMBL3143733 0.76 TSHR (0.36) ALDH1A1MAPTTP53CYP3A4TSHR
SCHEMBL3143729 0.76 TSHR (0.36) ALDH1A1MAPTTP53CYP3A4TSHR
SCHEMBL3148695 0.73 HRH3 (0.40) CYP3A4TSHRPARP15PARP10
SCHEMBL3144469 0.73 RAB9A (0.42) ALDH1A1TP53CYP3A4TSHRSMN1; SMN2
SCHEMBL3138904 0.73 GRM2 (0.58) MAPTSMN1; SMN2GPR84
SCHEMBL3138894 0.73 GRM2 (0.58) MAPTSMN1; SMN2GPR84
SCHEMBL3142637 0.72 HRH3 (0.42) CYP2C9CYP3A4SMN1; SMN2HIF1APARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137193-B1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2017-08-09 EP disclosed
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 US disclosed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 US disclosed
EP-2137193-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF Sanofi-Aventis (FR) 2009-12-30 EP disclosed
WO-2008112483-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF GRM2, GRM1, GRIN2C ALDH1A1 1875/4885MAPT 1382/4885CYP2C9 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.